Artesunate Regulates Neurite Outgrowth Inhibitor Protein B Receptor to Overcome Resistance to Sorafenib in Hepatocellular Carcinoma Cells

• Main Authors: Wubin He (Author), Xiaoxu Huang (Author), Bradford K. Berges (Author), Yue Wang (Author), Ni An (Author), Rongjian Su (Author), Yanyan Lu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-02-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The multireceptor tyrosine kinase inhibitor sorafenib is a Food and Drug Administration-approved first-line drug for the treatment of advanced liver cancer that can reportedly extend overall survival in patients with advanced hepatocellular carcinoma (HCC). Primary and acquired resistance to sorafen...